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Background: High HIV-1 DNA levels in peripheral blood mononuclear cells (PBMC) were associated with
a higher risk of severe morbidity and a faster decline in CD4 count in ART-naive patients. We report
the association between HIV-1 DNA and mortality in HIV-infected adults in a trial of early ART in
West Africa.
Methods: In the Temprano trial, HIV-infected adults were randomly assigned to start ART immediately or
defer ART. After trial termination, HIV-1 DNA was measured in whole blood samples frozen at baseline. We
analyzed the association between baseline PBMC HIV-1 DNA and long-term mortality.
Findings: 2019 patients were followed for 9253 patient-years (median 4.9 years). At baseline, the median CD4
count was 462/mm3 [IQR 368571], the median plasma HIV-1 RNA 4.7 log10 copies/ml [IQR 4.05.2], and the
median HIV-1 DNA 2.9 log10 copies/million PBMC [IQR 2.53.3]. During follow-up, 86 participants died. In
univariate analysis, the hazard ratio [HR] of death was 2.67 (95% CI, 1.684.22) for patients with HIV-1 DNA
3 log10 copies/million PBMC vs. others, and 2.10 (95% CI, 1.383.21) for patients with HIV-1 RNA 5
log10 copies/ml vs. others. In multivariate Cox regression analysis, HIV-1 DNA levels 3 log10 copies/million
PBMC were strongly associated mortality (adjusted HR = 2.09, 95% CI 1.243.52, p= 0.005) while the associa-
tion between baseline plasma HIV-1 RNA and mortality was not significant.
Interpretation: In these African adults who started ART with high CD4 counts, HIV-1 DNA was a strong inde-
pendent predictor of death. The HIV reservoir still plays a prognostic role in the early ART era.
Funding: This trial was supported by the French National Agency for AIDS and viral hepatitis research (ANRS,
Paris, France; Grants ANRS 12136, 12224 and 12253)
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The persistence of the Human Immune deficiency Virus (HIV) in
reservoirs is a obstacle to its eradication [1,2]. The reservoir of
infected cells is established very early and then influences the evolu-
tion of the disease [3]. HIV-1 DNA level in Peripheral Blood Mononu-
clear Cells (PBMC) is a proxy for reservoir size [4,5]. Previous studiesshow that HIV-1 DNA predicts HIV disease progression in untreated
subjects, therapeutic success in people on antiretroviral therapy
(ARV), and virologic rebound in subjects with treatment failure, all of
this independently of CD4 count and plasma HIV-1 RNA level [69].
These studies were mainly cohorts conducted in industrialized coun-
tries with relatively small numbers of participants, and before the
WHO recommendation that all HIV-infected individuals should be
treated regardless of their clinical, immunological or virological sta-
tus [1012].
We conducted the Temprano trial between 2008 and 2015. Tem-
prano was a randomized controlled trial evaluating the benefits and
risks of early ART and isoniazid preventive therapy (IPT) in HIV-
RESEARCH IN CONTEXT
Evidence before this study
We searched PubMed with search terms “HIV-1 DNA [Title]
AND (clinical OR Prognosis or death), on July 31, 2019, for
articled published in English. There were no date restrictions.
Before this study, evidence from cohort studies suggested that
HIV-1 DNA predicts HIV disease progression in untreated sub-
jects, therapeutic success or failure in people on antiretroviral
therapy (ARV), and virologic rebound in subjects with treat-
ment failure, all of this independently of CD4 count and plasma
HIV-1 RNA level. These studies were conducted before WHO
recommended that all HIV-infected individuals should start
ART regardless of their clinical, immunological or virological
status.
Added value of this study
We analyzed the association between HIV-1 DNA in PBMC and
long-term mortality in African adults who started ART early.
We found that patients with high HIV-1 DNA level at baseline
had a higher 6-year mortality risk than other patients, irrespec-
tive of plasma viral load, CD4 cell count and ART. This is the first
study to report this association. Previous cohort studies con-
ducted in industrialized countries with shorter follow-ups have
shown that high DNA levels are closely associated with the
prognosis, using an outcome combining severe morbidity, mor-
tality and CD4 cell count evolution. This study also help put
into perspective the practical utility of cellular HIV-1 DNA and
plasma HIV-1 RNA in clinical monitoring. Even if baseline HIV-1
DNA and RNA levels were significantly correlated, the correla-
tion had a poor coefficient, suggesting a different role for these
two markers in the pathophysiology of HIV-1 infection. The
association observed in univariate analysis between pre-thera-
peutic plasma HIV-1 RNA and mortality was quashed by the
effect of cellular HIV-1 DNA in multivariate analysis, which sug-
gests that infected cells play a major role in the progression of
the disease. Therefore, with regard to pre-therapeutic markers,
HIV-1 DNA seems to be a better predictor of the long-term
prognosis. In terms of on-treatment markers though, HIV-RNA
is the gold standard for monitoring ART efficacy.
Implications of all the available evidence
The reservoir of HIV-1 continues to play a key role in the prog-
nosis in patients who start ART early, regardless of plasma viral
load. Cellular HIV-1 DNA is an interesting clinical marker for
use in future research. At present, the pre-therapeutic level of
DNA can be used as a predictor of treatment success. In the
future, the evolution of HIV-1 DNA under treatment may
become attractive for comparing new strategies with effective
reservoir action.
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were followed for 30 months and the primary endpoint was severe
morbidity [10]. At the end of the 30-month follow-up, each patient
was invited to participate in a prolonged post-trial follow-up until
the last patient in Temprano had completed the 30 months of follow-
up (January 2015). The endpoint of the post-trial phase was mortality
[13].
In the present article, we look for an association between HIV-1
DNA levels in PBMC and long-term mortality in HIV-infected adults
who participated in Temprano.2. Methods
2.1. Temprano trial
Temprano was a 2 £ 2 factorial RCT conducted in Côte d’Ivoire.
The trial design and results have been reported previously [10]. In
summary: the inclusion criteria were HIV infection, age 18 years,
CD4 count 800/mm3 and no criteria for starting ART according to
the most recent WHO guidelines. Participants were randomized into
one of four arms: Arm-1 (‘Deferred-ART’), in which ART was deferred
until the WHO criteria for starting ART were met; Arm-2 (‘Deferred-
ART+IPT’), in which ART was deferred and a 6-month IPT was pre-
scribed; Arm-3 (‘Immediate-ART’), in which ART was started immedi-
ately; Arm-4 (‘Immediate -ART+IPT’), in which ART was started
immediately and a 6-month IPT was prescribed.
After randomization, all participants had a series of blood tests
including CD4 count and plasma HIV-1 RNA. Plasma and whole blood
samples were also frozen at 80 °C. All participants were followed
for 30 months. The primary endpoint was severe morbidity, defined
as a combination of all-cause deaths, AIDS diseases, non-AIDS malig-
nancies and non-AIDS-invasive bacterial diseases. The main results of
the Temprano trial at month 30 were that early ART and IPT both
reduced severe morbidity significantly [10].
2.2. Post-trial phase
The first Temprano participant completed 30 months of follow-up
in September 2010. From this date on, it was suggested to all patients
who reached their 30-month visit that they continue to be followed
in a post-trial phase until the last patient had completed the 30
months of follow-up specified for the trial [13].
Temprano and the post-trial phase had similar procedures. In the
post-trial phase, as in Temprano: patients made quarterly visits to their
care center; CD4 count and plasma HIV-1 RNAwere measured every six
months; CD4 count, viral load and antiretroviral drugs were supplied
free of charge; patients who did not attend for a trial appointment were
traced by experienced social workers. Patients followed in the post-trial
phase were subject to the same rules regarding ART prescription as
those who were still being followed for the trial in the same calendar
period. Patients assigned to the Deferred-ART strategy started ART
when they reached the most recent WHO criteria for starting ART, dur-
ing the trial if these criteria were met <30 months after enrolment, or
during the post-trial phase if the criteria were met >30 months after
enrolment. Patients who did not reach these criteria before the closing
date never started ART, either during the trial or in the post-trial phase.
Death assessment procedures were exactly the same during the trial
and post-trial phases, including verification of evidence of death by an
event documentation committee. However, access to care and treat-
ment other than ART differed between the trial and post-trial phases. In
case of a morbidity event in the trial phase, transportation for unsched-
uled visits, investigations, hospital admission, and non-antiretroviral
drugs were free of charge. In the post-trial phase, patients had to pay for
tests and treatment, just as any other patient followed up in routine
condition in the same care center. Due to these differences, the valida-
tion of diagnoses by the Event Documentation Committee was limited
to the trial phase.
2.3. HIV-1 DNA measurement
PBMC HIV-1 DNA levels were measured on whole blood samples
frozen at baseline. The HIV-1 DNA real time PCR was performed in
the laboratory of virology at the Necker University Hospital in Paris.
The technique was based on the amplification of the Long Terminal
Repeat (LTR) gene well adapted to HIV-1 non B sutypes and referring
to the 8E5 cell line containing one HIV copy per cell (HIV DNA cell,
Biocentric, Bandol, France) [14]. The threshold of the technique was 5
J.B. N'takpe et al. / EBioMedicine 56 (2020) 102815 3copies of HIV-1 DNA per PCR well. The HIV-1 DNA load was
expressed as a proportion of infected cells among the target cells.
Results were expressed as the HIV-1 DNA log10 copy number per mil-
lion PBMC [3,5]. HIV1 RNA levels were measured using the Biocentric
assay as previously reported [10].
2.4. Statistical analysis
We used the Kaplan-Meir method to estimate the cumulative proba-
bility of death. Mortality rates were estimated by dividing the number of
deaths by the cumulative person time at risk. The time at risk started at
randomization and ended on January 5, 2015. Follow-up data were cen-
sored when participants died or were lost to follow-up. Patients were
defined as lost-to-follow-up if they did not attend their last scheduled
appointment and no further information on their vital status was avail-
able within the 6months preceding the closing date of the database.
Cox proportional hazards models were used to look for an associa-
tion between baseline PBMC HIV-1 DNA level and mortality by the end
of the post-trial phase, adjusting the Hazard Ratio for the trial strategies
(Early-ART vs. Deferred-ART; IPT vs. no-IPT), baseline CD4 cell count,
baseline plasma HIV-1 RNA level, age, sex, and trial center (as a random
effect). We refer to trial ‘strategies’ whenever data combining patients
assigned to ‘IPT’ (arm-2-and-4), ‘No-IPT’ (arm-1-and-3), ‘Early-ART’
(arm-3-and-4) and ‘Deferred-ART’ (arm-1-and-2) is given.
We then carried out two sensitivity analyses: (i) we replaced






Excluded from analysis, n=17 (2)
Excluded early, n=1
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trial, n=970
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Allocated to strategy “Deferred-ART”, n=1035
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Fig. 1. Temprano trial and post-trial Flow Chart.
[1] 20 patients who underwent randomization were excluded early (see detail in Referen
[2] These patients were alive and followed up at the end of Temprano long term follow-u
1 DNA values at baseline.for actual ART initiation as a time-dependent variable; (ii) we cen-
sored follow-up at the time of ART initiation to better appreciate the
association between HIV-1 DNA and mortality during the period
when patients did not receive ART.
The interaction between variables was tested. The assumption of
the proportional hazards was examined. Statistical analyses were
performed with SAS 9.3 software.
2.5. Funder, registration and ethics
At the end of the 30-month follow-up for the trial, we asked
patients to renew their informed consent for participating in the
post-trial phase. The Temprano protocol, which included the post-
trial phase, was approved by the Côte d'Ivoire National Ethics Com-
mittee for Health Research. It was registered at Clinical Trials.gov
(NCT00495651). The sponsor (Agence Nationale de Recherches sur le
Sida et les hepatites virales) had no role in the conduct of the study
and interpretation of the data.
3. Results
3.1. Baseline and follow-up characteristics
Between March 2008 and July 2012, 2076 patients were included
in Temprano and randomly assigned to start ART immediately
(N = 1041) or to defer ART until the WHO criteria for starting ARTNot included, n=886 
Excluded early, n=8 (1)
Analyzed, n=1013
Excluded from analysis, n=20 (2)
2 (1)
Lost to follow-up, n=31
Death, n=21
Alive and followed up at the end of Temprano 
trial, n=981
Lost to follow-up, n=60
Deaths, n=16 
Alive and followed up at the end of the Post 
Trial Phase, n=905




p but were excluded from analysis for the present paper because they had missing HIV-
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were included in the Temprano analysis at 30 months. All partici-
pants who were still alive and followed up at 30 months agreed to
participate in the post-trial phase. Of the 2056 patients included in
the Temprano analysis, 37 (1.8%) were further excluded because of
missing HIV-1 DNA value at baseline, and 2019 were included in the
present analysis (Fig. 1).
Baseline and follow-up characteristics of the 2019 patients are
shown in Table 1.
The 2019 participants were followed for a total 9253 person-
years, including 4674 during the trial and 4579 during the post-trial
phase. The median follow-up time was 4.9 years overall (Interquartile
Range [IQR] 3.4 - 5.8). Of the 2019 patients, 1601 (79%) ever started
ART, including: 1013 who were randomized in the immediate ART
Temprano strategy and therefore started ART at inclusion; and 588
who were randomized in the deferred ART strategy and later met the
most recent WHO starting criteria during follow-up.
Baseline HIV-1 RNA and HIV-1 DNA levels were significantly cor-
related (Spearman's correlation: R = 0.59; p<0.0001) (Fig. 2). At theTable 1
Baseline and follow up characteristics (n = 2019).
Baseline
Age, years, median (IQR) 35 (3042)
Sex, female, n (%) 1584 (78)
Randomized to, n (%)
Deferred ART 1006 (49.8)
Early ART 1013 (50.2)
WHO clinical stage 1 or 2, n (%) 1822 (90)
CD4 cell count/mm3





Plasma HIV-1 RNA, log10 copies/ml
Median (IQR) 4.7 (4.05.2)
Categories, n (%)*
<5 log10 copies/ml 1315 (65)
5 log10 copies/ml 699 (35)
PBMCs HIV-1 DNA, log10 copies/106
Median (IQR) 2.9 (2.53.3)
Categories, n (%)
<3 log10 copies/106 1089 (54)
3 log10 copies/106 930 (46)
Follow-up
Ever started ART, n (%) 1601 (79)
First-line regimen, n (%)
TDFFTC plus EFV 1113 (70)
TDFFTC plus LPV/r 372 (23)
Other x 116 (7)
Duration of follow up, patient-years
Overall follow-up 9253
Temprano trial 4674
Post Trial Phase 4579
Lost to follow-up, n (%)
Overall follow-up 206 (10.2)
Temprano trial 57 (2.8)
Post Trial Phase 149 (7.4)
Death, n (%)
Overall follow-up 86 (4.3)
Temprano trial 47 (2.3)
Post Trial Phase 39 (1.9)
IQR: Interquartile range: WHO: World Health Organization ; ART: Antire-
troviral Therapy; TDF: tenofovir; FTC: emtricitabine; ZDV: zidovudine;
LPV/r: Lopinavir/ritonavir; PBMC: Peripheral Blood Mononuclear Cells;
DNA: deoxyribonucleic acid; RNA: ribonucleic acid; x Other regimens
were : TDF-FTC-ZDV (n = 80); ZDV-3TC-LPV/r (n = 25); ZDV-3TC-EFV
(n = 3); ZDV-3TC-nevirapine (n = 3); didanosine-3TC-EFV(n = 1); stavu-
dine-3TC-EFV(n = 1); stavudine-3TC-LPV/r (n = 1); 3TC-abacavir-LPV/r
(n = 1); TDF-FTC-stavudine (n = 1); * N = 2014 (5 missing values).end of the post trial phase, 206/2019 (10.2%) patients were lost to fol-
low-up, including 106/1089 (9.7%) patients with baseline PBMC HIV-
1 DNA <3 and 100/930 (10.8%) with baseline PBMC HIV-1 DNA 3
log10 copies/106 cells.3.2. HIV-1 DNA and risk of death
During follow-up, 86 deaths were recorded. The percentage of
deaths increased with increasing baseline PBMC HIV-1 DNA value.
The number and percentage of death among the total number of
patients having a baseline HIV-1 DNA <2, 2  DNA < 2.5, 2.5  DNA
< 3, 2.5  DNA < 3 and DNA  3.5 log10 copies/106 PBMC was 3/183
(1.6%), 6/311 (1.9%), 17/595 (2.9%), 35/665 (5.3%), and 25/265 (9.4%),
respectively.
The incidence of death was 1.40 per 100 person-years in patients
with baseline HIV-1 DNA  3 and 0.52 per 100 person-years in
patients with baseline HIV-1 DNA <3 log10 copies/106 PBMC. The 6-
year probability of death was 7.9% (95% CI 6.110.3) in patients with
baseline HIV-1 DNA  3 and 3.4% (95% CI 2.25.2) in patients with
baseline HIV-1 DNA <3 (Fig. 3a). The median time to death was 40.3
months (IQR 27.053.4) in patients with baseline HIV-1 DNA <3
log10 copies/106 PBMC and 23.6 months (7.940.2) in those with
HIV-1 DNA  3 log10 copies/106 PBMC.
The Hazard Ratio of death for patients with baseline HIV-1 DNA
 3 compared to baseline HIV-1 DNA <3 was 2.67 (95% CI
1.684.22) in univariate analysis, and 2.09 (95% CI 1.243.52) in
multivariate analysis adjusted for the ART strategy, IPT, trial center,
baseline CD4 count, sex, age and plasma HIV-1 RNA. Other factors
significantly associated with death were IPT and plasma HIV-1 RNA
in univariate analysis. In multivariate analysis, the risk of death
remained significantly higher in patients with no IPT, but was no
longer significantly associated with baseline plasma HIV-1 RNA
(Table 2).
Fig. 3b shows the probability of death over time by groups of HIV-
1 DNA and HIV-1 RNA. The 6-year probability of death was 7.7% in
patients with HIV-1 DNA  3 and HIV-1 RNA  5, 5.3% in patients
with HIV-1 DNA  3 and HIV-1 RNA <5, 4.3% in patients with HIV-1
DNA <3 and HIV-1 RNA  5, and 2.3% in patients with HIV-1 DNA
<3 and HIV-1 RNA <5.
Fig. 3c shows the probability of death over time by groups of
HIV-1 DNA and Temprano ART strategy. The 6-year probability of
death was 8.8% in patients randomized to deferred ART with HIV-1
DNA  3, 3.4% in patients randomized to deferred ART with HIV-1
DNA <3, 6.9% in patients randomized to early ART with
HIV-1 DNA  3, and 3.4% in patients randomized to early ART with
HIV-1 DNA <3.
Of the 86 deaths, 56 were considered to be of unknown cause. In
the case of 30 deaths, a possible or probable cause was identified
(Table SA1 in the Supplemental Appendix). The percentage of deaths
with identified causes was similar in patients baseline HIV-1 DNA 3
log10copies/106 PBMC and in those with HIV-1 DNA <3 (21/60 [35%]
vs. 9/26 [35%], p = 0.97). In patients who started ART, the last available
plasma viral load was more frequently detectable in patients with
baseline HIV-1 DNA  3 (23% vs. 18%); and the percentage of patients
who died among those with detectable viral load tended to be higher
in patients with baseline HIV-1 DNA  3 (7% vs. 3%)(Table SA2 in the
Supplemental Appendix).3.3. Sensitivity analysis
The Hazard Ratios of patients with HIV-1 DNA  3 compared to
<3 and patients with HIV-1 RNA  5 compared to<5 remained simi-
lar in univariate and multivariate analysis when the Temprano ART
strategy was replaced with actual ART initiation and when censoring
follow-up at ART initiation (Table 2).
Fig. 2. Spearman's correlation between plasma HIV-1 RNA and PBMC HIV-1 DNA levels (N = 2014).
PBMC: Peripheral Blood Mononuclear Cells; DNA: deoxyribonucleic acid; RNA: ribonucleic acid; Spearman's correlation coefficient: R = 0.59, p<0.0001.
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We analyzed the association between HIV-1 DNA in PBMC and
medium-term mortality in African adults who started ART early, in a
country were patients are mainly infected with HIV-1 non B
subtypes.
We found that patients with high HIV-1 DNA level at baseline had
a higher 6-year mortality risk than other patients, irrespective of
plasma viral load, CD4 cell count and ART.
To the best of our knowledge, this is the first study to report this
association. Previous cohort studies conducted in industrialized
countries with shorter follow-ups have shown that high DNA levels
are closely associated with the prognosis, using an outcome combin-
ing severe morbidity, mortality and CD4 cell count evolution
[3,8,9,1517]. In previous studies, a low level of pre-therapeutic HIV-
1 DNA was also associated with the virological success of ART
[7,1821].
The distribution of HIV-1 DNA levels in our patients was very sim-
ilar to the one we previously measured in a cohort of recently-
infected adults in Abidjan in the 1990s [15,16]. This is consistent
with the long-acknowledged notion that the reservoir is established
very early in infection and varies little thereafter [22].
Our findings help put into perspective the practical utility of cellu-
lar HIV-1 DNA and plasma HIV-1 RNA in clinical monitoring. Baseline
HIV-1 DNA and RNA levels were significantly but moderately corre-
lated, suggesting a different role for these two markers in the patho-
physiology of HIV-1 infection. The association observed in univariate
analysis between pre-therapeutic plasma HIV-1 RNA and mortality
was quashed by the effect of cellular HIV-1 DNA in multivariate anal-
ysis, which suggests that infected cells play a major role in the pro-
gression of the disease. Therefore, with regard to pre-therapeutic
markers, HIV-1 DNA seems to be a better predictor of the long-term
prognosis. In terms of on-treatment markers though, HIV-RNA is the
gold standard for monitoring ART efficacy. Under effective ART,
plasma HIV-1 RNA becomes undetectable while cellular HIV-1 DNAdecreases slightly but remains at a level close to the pre-therapeutic
level [23]. For HIV-1 DNA to become a useful marker for treatment
monitoring and comparing treatment strategies in research, we
would need powerful new treatments for HIV with effective reservoir
action [24].
In our study, both early-ART and actual ART initiation tended to
reduce the risk of death compared to deferred-ART, but this did not
reach significance. This may be due to a lack of power. Our study was
supported by a large sample size and a long follow-up period. Our
findings were robust in sensitivity analyses. However, there were
also several limitations.
Firstly, the association of a marker with the prognosis in a cohort
study must be interpreted with caution, as there is always the possi-
bility of one or several confounding factors unrecorded in the
database.
Secondly, while we reported the rate of severe morbidity events
at 30 months in the initial Temprano paper, long-term morbidity
data is not reported in the present paper. During the trial phase, the
Event Documentation Committee used standardized criteria to vali-
date and classify all severe morbidity events. These criteria were a
combination of clinical definitions and laboratory and radiological
test results. Some clinical definitions included evolution under stan-
dardized care and treatment [10]. During the post-trial phase, partici-
pants had to pay for tests other than routine ART monitoring tests,
and for care and treatment other than ART. Therefore, we did not
document morbidity events during the PTP but focused our efforts on
documenting mortality.
In conclusion, the reservoir of HIV-1 continues to play a key role in
the prognosis in patients who start ART early, regardless of plasma
viral load. Cellular HIV-1 DNA is an interesting clinical marker for use
in future research. At present, the pre-therapeutic level of DNA can
be used as a predictor of treatment success. Since HIV-1 DNA does
not decrease significantly on ART, measuring DNA in patients on ART
would currently not be of much use on a routine basis. However, if
new treatments were to have the effect of reducing the reservoir in
Fig. 3. (a) Kaplan Meier curve of probability of death, by baseline PBMC HIV-1 DNA level (N = 2019).
PBMC: Peripheral Blood Mononuclear Cells; DNA: deoxyribonucleic acid; RNA: ribonucleic acid; Log-rank: p<0.0001.
(b) Kaplan Meier curve of probability of death, by baseline PBMC HIV-1 DNA level and baseline plasma HIV-1 RNA level (N = 2014).
PBMC: Peripheral Blood Mononuclear Cells; DNA: deoxyribonucleic acid; RNA: ribonucleic acid; Log-rank: p<0.0001.
(c) Kaplan Meier curve of probability of death, by baseline PBMC HIV-1 DNA level and Temprano ART strategy (N = 2019).
PBMC: Peripheral Blood Mononuclear Cells; DNA: deoxyribonucleic acid; ART: Antiretroviral Therapy; Log-rank: p<0.0001.
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Table 2
Baseline characteristics associated with the risk of death.
Univariate analysis Multivariate analysis (N = 2014)
HR 95% IC p aHR 95% IC p
ART strategy: early vs. deferred 0.74 0.481.13 0.17 0.76 0.491.16 0.20
IPT strategy: yes vs. no 0.64 0.410.98 0.04 0.63 0.410.97 0.03
Sex: Male vs. female 1.50 0.942.39 0.08 1.39 0.862.24 0.17
Plasma HIV-1 RNA:  5 vs. < 5 log10 copies/ml 2.10 1.383.21 0.0006 1.44 0.902.32 0.13
PBMC HIV-1 DNA:  3 vs. < 3 log10 copies/106 cells 2.67 1.684.22 <0.0001 2.09 1.243.52 0.005
CD4+ cell count: 0.18 0.31
350500 vs. <350 cells/mm3 0.90 0.541.48 0.67 0.99 0.591.64 0.96
500 vs. <350 cells/mm3 0.60 0.341.06 0.08 0.68 0.371.21 0.19
Characteristics associated with the risk of death, sensitivity analysis N°1: replacing Temprano ART strategy with actual ART initiation
Univariate analysis* Multivariate analysis* N = 2014
HR 95% IC p aHR 95% IC p
ART really started 1 0.91 0.541.52 0.71 0.78 0.461.34 0.37
IPT strategy: yes vs. no 0.64 0.410.98 0.04 0.63 0.410.97 0.04
Sex: Male vs. female 1.50 0.942.39 0.08 1.39 0.862.24 0.18
Plasma HIV-1 RNA:  5 vs. < 5 log10 copies/ml 2.10 1.383.21 0.0006 1.44 0.892.32 0.13
PBMC HIV-1 DNA:  3 vs. < 3 log10 copies/106 cells 2.67 1.684.22 <0.0001 2.12 1.263.57 0.005
CD4+ cell count: 0.18 0.26
350500 vs. <350 cells/mm3 0.90 0.541.48 0.67 0.97 0.581.61 0.89
500 vs. <350 cells/mm3 0.60 0.341.06 0.08 0.64 0.361.17 0.15
Characteristics associated with the risk of death, sensitivity analysis N°2: patients randomized to deferred ART strategy with follow-up censored at ART initiation
Univariate analysis* Multivariate analysis* N = 1004
HR 95% IC p aHR 95% IC p
IPT strategy: yes vs. no 0.35 0.140.90 0.029 0.32 0.130.83 0.018
Sex: Male vs. female 1.47 0.603.57 0.40 1.38 0.553.50 0.49
Plasma HIV-1 RNA:  5 vs. < 5 log10 copies/ml 4.75 2.0111.2 0.0004 2.68 1.076.69 0.035
PBMC HIV-1 DNA:  3 vs. < 3 log10 copies/106 cells 7.25 2.4521.42 0.0003 4.99 1.5715.82 0.006
CD4+ cell count: 0.31 0.37
350500 vs. <350 cells/mm3 0.92 0.292.92 0.89 0.90 0.282.90 0.86
500 vs. <350 cells/mm3 0.48 0.141.62 0.24 0.48 0.141.72 0.26
N : number of patient; HR : Hazard ratio; aHR : adjusted Hazard ratio (Adjusted for study centre and for all other variables shown in the table); ART: antiretroviral treat-
ment; IPT : Isoniazid preventive therapy; CI: confidence interval; PBMC: Peripheral BloodMononuclear Cells; DNA: deoxyribonucleic acid; RNA: ribonucleic acid.
*Cox proportional hazards models; N : number of patient; aHR : adjusted Hazard ratio (adjusted for study centre and for all other characteristics shown in the table);
IPT : Isoniazid preventive therapy; CI: confidence interval: PBMC: Peripheral Blood Mononuclear Cells; DNA: deoxyribonucleic acid; RNA: ribonucleic acid; (1): ART
was started vs. ART was never started (time dependant variable) during trial and post-trial follow-up.
*Cox proportional hazards models ; N : number of patient; aHR : adjusted Hazard ratio (adjusted for study centre and for all other characteristics shown in the table);
IPT: Isoniazid preventive therapy; CI: confidence interval: PBMC: Peripheral Blood Mononuclear Cells; DNA: deoxyribonucleic acid; RNA: ribonucleic acid.
J.B. N'takpe et al. / EBioMedicine 56 (2020) 102815 7the future, the evolution of HIV-1 DNA under treatment would
become an important marker for evaluating the effectiveness of these
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